INTRODUCTION Detection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non-small-cell lung cancer (NSCLC) is mainly performed by fluorescence in-situ hybridization (FISH). The question was raised if FISH might be replaced by immunohistochemistry (IHC) in a reliable and reproducible manner across different laboratories. METHODS After calibration of the staining instruments and training of the observers to binary interpretation (positive versus negative), 15 NSCLC were independently tested for ALK protein expression by IHC only in a multicenter setting (16 institutes). Each laboratory utilized the VENTANA ALK-D5F3 IHC assay. As demonstrated by FISH the samples displayed unequivocal ALK break-positivity (6×) and negativity (7×), ...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...
IntroductionDetection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non–small-cell lung...
Background:The use of a standard immunohistochemistry (IHC) assay to detect the anaplastic lymphoma ...
Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NS...
Introduction:The goal of personalized medicine is to treat patients with a therapy predicted to be e...
INTRODUCTION: Lung cancer is often diagnosed by cytology, necessitating predictive molecular marker ...
IntroductionFluorescence in situ hybridization (FISH) is currently the standard for diagnosing anapl...
International audienceIntroduction: Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7...
Abstract Background Rearrangements of the anaplastic lymphoma kinase (ALK) belong to the promising t...
Patients and methods Testing for Anaplastic Lymphoma Kinas (ALK) rearrangement is now recommended fo...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
Introduction: The 2018 updated molecular testing guidelines for patients with advanced lung cancer i...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...
IntroductionDetection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non–small-cell lung...
Background:The use of a standard immunohistochemistry (IHC) assay to detect the anaplastic lymphoma ...
Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NS...
Introduction:The goal of personalized medicine is to treat patients with a therapy predicted to be e...
INTRODUCTION: Lung cancer is often diagnosed by cytology, necessitating predictive molecular marker ...
IntroductionFluorescence in situ hybridization (FISH) is currently the standard for diagnosing anapl...
International audienceIntroduction: Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7...
Abstract Background Rearrangements of the anaplastic lymphoma kinase (ALK) belong to the promising t...
Patients and methods Testing for Anaplastic Lymphoma Kinas (ALK) rearrangement is now recommended fo...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
Introduction: The 2018 updated molecular testing guidelines for patients with advanced lung cancer i...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...